Exome sequencing identifies MAX mutations as a cause

Nature Genetics

43, 663-667

DOI: 10.1038/ng.861

Citation Report

#	Article	IF	Citations
5	Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocrine-Related Cancer, 2011, 18, R253-R276.	3.1	299
6	Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles. PLoS Genetics, 2012, 8, e1002894.	3.5	186
7	Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene Mutations. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E954-E962.	3.6	87
8	Mitochondrial function and content in pheochromocytoma/paraganglioma of succinate dehydrogenase mutation carriers. Endocrine-Related Cancer, 2012, 19, 261-269.	3.1	23
9	False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocrine-Related Cancer, 2012, 19, 83-93.	3.1	106
10	Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. Journal of Molecular Endocrinology, 2012, 49, 79-96.	2.5	44
11	Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocrine-Related Cancer, 2012, 19, 149-155.	3.1	71
12	ENDOCRINE DISORDERS IN PREGNANCY: Pheochromocytoma and pregnancy: a deceptive connection. European Journal of Endocrinology, 2012, 166, 143-150.	3.7	122
13	GENETICS IN ENDOCRINOLOGY: The genetics of phaeochromocytoma: using clinical features to guide genetic testing. European Journal of Endocrinology, 2012, 166, 151-158.	3.7	98
14	Genetic Testing by Cancer Site. Cancer Journal (Sudbury, Mass), 2012, 18, 364-371.	2.0	13
15	Elements of â€˜missing heritabilityâ€™. Current Opinion in Cardiology, 2012, 27, 197-201.	1.8	55
16	Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Human Molecular Genetics, 2012, 21, 5406-5416.	2.9	97
17	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics, 2012, 21, 5397-5405.	2.9	126
18	Trp53 inactivation leads to earlier phaeochromocytoma formation in pten knockout mice. Endocrine-Related Cancer, 2012, 19, 731-740.	3.1	3
19	Pheochromocytoma and Paraganglioma: Recent Progress and New Vistas for Improved Patient Care. Hormone and Metabolic Research, 2012, 44, 325-327.	1.5	8
20	Current and Future Anatomical and Functional Imaging Approaches to Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2012, 44, 367-372.	1.5	71
21	A Decade (2001-2010) of Genetic Testing for Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2012, 44, 359-366.	1.5	103
22	Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL). Hormone and Metabolic Research, 2012, 44, 411-414.	1.5	71

#	Article	IF	Citations
23	Genetic Screening for von Hippel-Lindau Gene Mutations in Non-syndromic Pheochromocytoma: Low Prevalence and False-positives or Misdiagnosis Indicate a Need for Caution. Hormone and Metabolic Research, 2012, 44, 343-348.	1.5	11
24	High Incidence of Cardiovascular Complications in Pheochromocytoma. Hormone and Metabolic Research, 2012, 44, 379-384.	1.5	138
25	A pelvic paraganglioma presenting as a hypertensive emergency in pregnancy. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2012, 17, 145-147.	0.2	1
26	Pheochromocytoma â€“ update on disease management. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 11-26.	3.2	70
27	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
28	The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocrine-Related Cancer, 2012, 19, 157-166.	3.1	55
29	Modern Nuclear Imaging for Paragangliomas: Beyond SPECT. Journal of Nuclear Medicine, 2012, 53, 264-274.	5.0	79
30	2012 Meet-The-Professor: Endocrine Case Management. , 2012, , .		0
32	Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology, 2012, 44, 285-292.	0.6	168
33	Identical germline mutations in the <scp>TMEM</scp>127 gene in two unrelated <scp>J</scp>apanese patients with bilateral pheochromocytoma. Clinical Endocrinology, 2012, 77, 707-714.	2.4	14
34	Molecular genetic studies of complex phenotypes. Translational Research, 2012, 159, 64-79.	5.0	121
35	Subclinical phaeochromocytoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 507-515.	4.7	76
36	Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genetics, 2012, 205, 1-11.	0.4	177
37	Regulation of gene transcription by the oncoprotein MYC. Gene, 2012, 494, 145-160.	2.2	118
38	Integrative analysis of neuroblastoma and pheochromocytoma genomics data. BMC Medical Genomics, 2012, 5, 48.	1.5	16
39	How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Review of Molecular Diagnostics, 2012, 12, 25-37.	3.1	15
40	Human Genome Sequencing in Health and Disease. Annual Review of Medicine, 2012, 63, 35-61.	12.2	404
41	Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Modern Pathology, 2012, 25, 1055-1068.	5.5	35

#	Article	IF	Citations
42	An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes. Hormone and Metabolic Research, 2012, 44, 328-333.	1.5	269
43	Neurofibromatosis Type 1. , 2012, , .		23
45	Improving Indel Detection Specificity of the Ion Torrent PGM Benchtop Sequencer. PLoS ONE, 2012, 7, e45798.	2.5	48
46	Updated and New Perspectives on Diagnosis, Prognosis, and Therapy of Malignant Pheochromocytoma/Paraganglioma. Journal of Oncology, 2012, 2012, 1-10.	1.3	106
47	Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging. Frontiers in Oncology, 2011, 1, 58.	2.8	33
49	Somatic Mutation Analysis of the SDHB, SDHC, SDHD, and RET Genes in the Clinical Assessment of Sporadic and Hereditary Pheochromocytoma. Hormones and Cancer, 2012, 3, 187-192.	4.9	20
50	MAX and MYC: A Heritable Breakup. Cancer Research, 2012, 72, 3119-3124.	0.9	144
52	Screening for Pheochromocytomas and Paragangliomas. Current Hypertension Reports, 2012, 14, 130-137.	3.5	34
53	Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2012, 23, 34-42.	9.0	75
54	Murine Models and Cell Lines for the Investigation of Pheochromocytoma: Applications for Future Therapies?. Endocrine Pathology, 2012, 23, 43-54.	9.0	30
55	From Transcriptional Profiling to Tumor Biology in Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2012, 23, 15-20.	9.0	16
56	Signaling Pathways in Pheochromocytomas and Paragangliomas: Prospects for Future Therapies. Endocrine Pathology, 2012, 23, 21-33.	9.0	57
57	Prevalence of Germline Mutations in Patients with Pheochromocytoma or Abdominal Paraganglioma and Sporadic Presentation: A Populationâ€Based Study in Western Sweden. World Journal of Surgery, 2012, 36, 1389-1394.	1.6	27
58	Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbeck's Archives of Surgery, 2012, 397, 155-177.	1.9	39
59	Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia. BMC Cancer, 2013, 13, 55.	2.6	24
60	Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma. Current Oncology Reports, 2013, 15, 356-371.	4.0	155
61	Impact of the next-generation sequencing data depth on various biological result inferences. Science China Life Sciences, 2013, 56, 104-109.	4.9	11
62	The Role of New Sequencing Technology in Identifying Rare Mutations in New Susceptibility Genes for Cancer. Current Genetic Medicine Reports, 2013, 1, 175-181.	1.9	1

#	Article	IF	Citations
63	Diagnostic Cancer Genome Sequencing and the Contribution of Germline Variants. Science, 2013, 339, 1559-1562.	12.6	57
64	An update on the genetics of pheochromocytoma. Journal of Human Hypertension, 2013, 27, 141-147.	2.2	54
65	Control of Vertebrate Development by MYC. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a014332-a014332.	6.2	35
66	Usefulness of Negative and Weakâ€“Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and Pheochromocytomas. Endocrine Pathology, 2013, 24, 199-205.	9.0	42
67	Genomics in Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 61, 2029-2037.	2.8	37
68	Role of Hypoxia and HIF2Î± in Development of the Sympathoadrenal Cell Lineage and Chromaffin Cell Tumors with Distinct Catecholamine Phenotypic Features. Advances in Pharmacology, 2013, 68, 285-317.	2.0	34
70	Diagnosis of silent pheochromocytoma and paraganglioma. Expert Review of Endocrinology and Metabolism, 2013, 8, 47-57.	2.4	11
71	Paragangliomas: Update on differential diagnostic considerations, composite tumors, and recent genetic developments. Seminars in Diagnostic Pathology, 2013, 30, 207-223.	1.5	40
72	Gestational diastolic hypertension with gene mutation-related pheochromocytoma positive at 18F-DOPA PET/CT: Diagnostic and therapeutic implications. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2013, 32, 111-112.	0.2	0
74	Translational Research in Endocrine Surgery. Surgical Oncology Clinics of North America, 2013, 22, 857-884.	1.5	11
75	Gestational diastolic hypertension with gene mutation-related pheochromocytoma positive at 18F-DOPA PET/CT: Diagnostic and therapeutic implications. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2013, 32, 111-112.	0.0	1
76	A new germline <scp>VHL</scp> gene mutation in three patients with apparently sporadic pheochromocytoma. Clinical Endocrinology, 2013, 78, 391-397.	2.4	5
77	Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clinical Endocrinology, 2013, 78, 165-175.	2.4	76
78	Clinical relevance of cancer genome sequencing. World Journal of Gastroenterology, 2013, 19, 2011.	3.3	16
79	Update on pediatric cancer predisposition syndromes. Pediatric Blood and Cancer, 2013, 60, 1247-1252.	1.5	50
80	10 rare tumors that warrant a genetics referral. Familial Cancer, 2013, 12, 1-18.	1.9	24
81	Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing. Annals of Surgical Oncology, 2013, 20, 1444-1450.	1.5	182
82	Overexpression of the insulinâ€like growth factor 1 receptor (<scp>IGF</scp>â€1<scp>R</scp>) is associated with malignancy in familial pheochromocytomas and paragangliomas. Clinical Endocrinology, 2013, 79, 623-630.	2.4	11

#	Article	IF	Citations
83	Novel Hereditary Forms of Pheochromocytomas and Paragangliomas. Frontiers of Hormone Research, 2013, 41, 79-91.	1.0	13
84	Mutation screening in a Norwegian cohort with pheochromocytoma. Familial Cancer, 2013, 12, 529-535.	1.9	8
85	p.N78S and p.R161Q germline mutations of the VHL gene are present in von Hippel-Lindau syndrome in two pedigrees. Molecular Medicine Reports, 2013, 8, 799-805.	2.4	6
86	Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma. Endocrine Connections, 2013, 2, 104-111.	1.9	37
87	The Genetic Landscape of Pheochromocytomas and Paragangliomas: Somatic Mutations Take Center Stage. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2679-2681.	3.6	18
88	Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation. Endocrine-Related Cancer, 2013, 20, 65-78.	3.1	24
89	Large Pheochromocytoma in the Third Trimester of Gestation. Case Report. Acta Endocrinologica, 2013, 9, 307-314.	0.3	0
90	Research and clinical applications of cancer genome sequencing. Current Opinion in Obstetrics and Gynecology, 2013, 25, 3-10.	2.0	14
91	Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Human Molecular Genetics, 2013, 22, 2169-2176.	2.9	142
92	Genetics of pheochromocytoma and paraganglioma syndromes. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 186-191.	2.3	51
93	A Comprehensive Next Generation Sequencingâ€“Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1248-E1256.	3.6	92
94	Molecular and Therapeutic Advances in the Diagnosis and Management of Malignant Pheochromocytomas and Paragangliomas. Oncologist, 2013, 18, 391-407.	3.7	41
95	Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. Endocrine-Related Cancer, 2013, 20, L1-L6.	3.1	44
96	Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction. Journal of the National Cancer Institute, 2013, 105, 1270-1283.	6.3	146
97	Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocrine-Related Cancer, 2013, 20, 477-493.	3.1	52
98	Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. Frontiers in Oncology, 2013, 3, 117.	2.8	44
99	Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes. Clinical Endocrinology, 2013, 79, 817-823.	2.4	38
100	Novel mutation in the <scp>TMEM</scp>127 gene associated with phaeochromocytoma. Internal Medicine Journal, 2013, 43, 449-451.	0.8	14

#	Article	IF	Citations
101	Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma. Journal of Clinical Hypertension, 2013, 15, 428-434.	2.0	62
102	Phospho-mTOR is not upregulated in metastaticSDHBparagangliomas. European Journal of Clinical Investigation, 2013, 43, 970-977.	3.4	10
103	No difference in phenotype of the main <scp>D</scp>utch <scp>SDHD</scp> founder mutations. Clinical Endocrinology, 2013, 79, 824-831.	2.4	9
104	Hereditary Neuroendocrine Tumor Syndromes. , 0, , .		3
105	Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles. PLoS ONE, 2013, 8, e55681.	2.5	95
106	Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature. OncoTargets and Therapy, 2013, 6, 1559.	2.0	6
107	Pathophysiology and Neoplasia of the Adrenal Medulla and Extra-Adrenal Paraganglia. , 2014, , 1223-1233.		0
108	High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma. PLoS ONE, 2014, 9, e90458.	2.5	9
109	Integrative Genetic Characterization and Phenotype Correlations in Pheochromocytoma and Paraganglioma Tumours. PLoS ONE, 2014, 9, e86756.	2.5	32
110	The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay. PLoS ONE, 2014, 9, e97408.	2.5	67
111	Management and follow up of extraadrenal phaeochromocytoma. Central European Journal of Urology, 2014, 67, 156-61.	0.3	15
112	Genetic predisposition to colorectal cancer: Where we stand and future perspectives. World Journal of Gastroenterology, 2014, 20, 9828.	3.3	71
113	Pathophysiology of Hypertension. , 2014, , 1-54.		0
114	Rare Germline Mutations Identified by Targeted Next-Generation Sequencing of Susceptibility Genes in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1352-E1360.	3.6	145
115	Phenotype of SDHB mutation carriers in the Netherlands. Familial Cancer, 2014, 13, 651-657.	1.9	9
117	Usefulness of <scp>S</scp>uccinate dehydrogenase B (<scp>SDHB</scp>) immunohistochemistry in guiding mutational screening among patients with pheochromocytomaâ€paraganglioma syndromes. Apmis, 2014, 122, 1130-1135.	2.0	24
118	Pathophysiology and Diagnosis of Disorders of the Adrenal Medulla: Focus on Pheochromocytoma. , 2014, 4, 691-713.		24
119	Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome. Neoplasia, 2014, 16, 868-873.	5.3	55

#	Article	IF	Citations
120	Pheochromocytoma and multiple endocrine neoplasia syndromes. , 2014, , 533-568.e1.		5
121	Paragangliomas/Pheochromocytomas: Clinically Oriented Genetic Testing. International Journal of Endocrinology, 2014, 2014, 1-14.	1.5	53
122	Pitfalls in Genetic Analysis of Pheochromocytomas/Paragangliomasâ€"Case Report. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2321-2326.	3.6	8
123	Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 837-44.	0.9	12
124	Multiple congenital anomaliesâ€intellectual disability (MCAâ€ID) and neuroblastoma in a patient harboring a de novo 14q23.1q23.3 deletion. American Journal of Medical Genetics, Part A, 2014, 164, 1310-1317.	1.2	9
125	An Overview of MYC and Its Interactome. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014357-a014357.	6.2	317
126	Hypoxia reduces MAX expression in endothelial cells by unproductive splicing. FEBS Letters, 2014, 588, 4784-4790.	2.8	14
127	Frequent EPAS1/HIF2Î± exons 9 and 12 mutations in non-familial pheochromocytoma. Endocrine-Related Cancer, 2014, 21, 495-504.	3.1	67
128	No small surpriseÂâ€“Âsmall cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. Journal of Pathology, 2014, 233, 209-214.	4.5	117
129	Fine needle biopsy with cytology in paediatrics: the importance of a multidisciplinary approach and the role of ancillary techniques. Cytopathology, 2014, 25, 6-20.	0.7	27
130	Paraganglioma and pheochromocytoma upon maternal transmission of SDHDmutations. BMC Medical Genetics, 2014, 15, 111.	2.1	38
131	Phaeochromocytoma and paraganglioma: next-generation sequencing and evolving Mendelian syndromes. Clinical Medicine, 2014, 14, 440-444.	1.9	7
132	Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 166-176.	2.3	20
133	Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocrine-Related Cancer, 2014, 21, 415-426.	3.1	34
134	Molecular genetics of paragangliomas of the skull base and head and neck region: implications for medical and surgical management. Journal of Neurosurgery, 2014, 120, 321-330.	1.6	15
135	MANAGEMENT OF ENDOCRINE DISEASE: Clinical management of paragangliomas. European Journal of Endocrinology, 2014, 171, R231-R243.	3.7	51
136	Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2014, 21, R261-R277.	3.1	31
137	Diagnosis and management of pheochromocytoma. Current Problems in Surgery, 2014, 51, 151-187.	1.1	47

#	Article	IF	Citations
138	MYC, MAX, and Small Cell Lung Cancer. Cancer Discovery, 2014, 4, 273-274.	9.4	11
139	MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours. Familial Cancer, 2014, 13, 121-125.	1.9	10
140	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232.	1.0	40
141	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. Cancer Cell, 2014, 25, 91-101.	16.8	847
142	Current concepts of pheochromocytoma. International Journal of Surgery, 2014, 12, 469-474.	2.7	40
143	Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genetics in Medicine, 2014, 16, 830-837.	2.4	281
144	Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nature Communications, 2014, 5, 3802.	12.8	34
146	Familial pheochromocytomas and paragangliomas. Molecular and Cellular Endocrinology, 2014, 386, 92-100.	3.2	47
147	Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nature Reviews Cancer, 2014, 14, 108-119.	28.4	442
148	Genetics, Diagnosis, and Management of Medullary Thyroid Carcinoma and Pheochromocytoma/Paraganglioma. Endocrine Practice, 2014, 20, 176-187.	2.1	14
149	Role of SDHAF2 and SDHD in von Hippelâ€“Lindau Associated Pheochromocytomas. World Journal of Surgery, 2014, 38, 724-732.	1.6	6
150	Realizing the promise of cancer predisposition genes. Nature, 2014, 505, 302-308.	27.8	483
151	Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. Current Problems in Cancer, 2014, 38, 7-41.	2.0	163
152	A Practical Guide to Human Cancer Genetics. , 2014, , .		8
153	Nextâ€generation sequencing for the genetic screening of phaeochromcytomas and paragangliomas: riding the new wave, but with caution. Clinical Endocrinology, 2014, 80, 23-24.	2.4	6
154	Long-term prognosis of patients with pediatric pheochromocytoma. Endocrine-Related Cancer, 2014, 21, 17-25.	3.1	121
155	Opposing effects of HIF1Î± and HIF2Î± on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064.	5.1	72
156	Cancer Genomics and Inherited Risk. Journal of Clinical Oncology, 2014, 32, 687-698.	1.6	121

#	Article	IF	Citations
157	Management of familial cancer: sequencing, surveillance and society. Nature Reviews Clinical Oncology, 2014, 11, 723-731.	27.6	27
158	Hereditary Pheochromocytoma. International Journal of Surgical Pathology, 2014, 22, 393-400.	0.8	32
159	MAX Inactivation in Small Cell Lung Cancer Disrupts MYCâ€“SWI/SNF Programs and Is Synthetic Lethal with BRG1. Cancer Discovery, 2014, 4, 292-303.	9.4	153
160	Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clinical Endocrinology, 2014, 80, 25-33.	2.4	35
161	Exome Sequencing in Familial Colorectal Cancer: Searching for Needles in Haystacks. Gastroenterology, 2014, 147, 554-556.	1.3	1
162	Extended Blood Group Molecular Typing and Next-Generation Sequencing. Transfusion Medicine Reviews, 2014, 28, 177-186.	2.0	41
163	Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1915-1942.	3.6	2,031
164	Genomics and transcriptomics in drug discovery. Drug Discovery Today, 2014, 19, 126-132.	6.4	54
165	Wholeâ€exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT 2 D as a recurrently mutated gene. Genes Chromosomes and Cancer, 2015, 54, 542-554.	2.8	57
169	Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer, 2015, 15, 887.	2.6	30
170	Pheochromocytomas and Paragangliomas. Advances in Anatomic Pathology, 2015, 22, 283-293.	4.3	17
171	Malignant pheochromocytoma in the elderly. Nuclear Medicine Communications, 2015, 36, 1159-1164.	1.1	2
173	Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. Frontiers in Endocrinology, 2015, 6, 126.	3.5	18
174	Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma. PLoS ONE, 2015, 10, e0133210.	2.5	11
175	Update on paragangliomas and pheochromocytomas. Turk Patoloji Dergisi, 2015, 31 Suppl 1, 105-12.	0.3	14
176	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	5.5	176
177	Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 169-179.	2.3	35
178	Neuroendocrine Tumours. , 2015, , .		6

#	Article	IF	Citations
179	Pheochromocytoma and Paraganglioma. , 2015, , 419-435.		0
180	Metastatic pheochromocytoma and paraganglioma. European Journal of Clinical Investigation, 2015, 45, 986-997.	3.4	47
181	15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma. Endocrine-Related Cancer, 2015, 22, T83-T90.	3.1	9
182	15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2015, 22, T123-T133.	3.1	54
183	A pathologist's view: molecular profiles for diagnosing pheochromocytomas and paragangliomas. International Journal of Endocrine Oncology, 2015, 2, 193-200.	0.4	4
184	MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy. Cellular and Molecular Life Sciences, 2015, 72, 417-428.	5.4	49
185	SDHD Immunohistochemistry: A New Tool to ValidateSDHxMutations in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E287-E291.	3.6	45
186	The genomic landscape of phaeochromocytoma. Journal of Pathology, 2015, 236, 78-89.	4.5	61
187	Exome Sequencing and CNV Analysis on Chromosome 18 in Small Intestinal Neuroendocrine Tumors: Ruling Out a Suspect?. Hormone and Metabolic Research, 2015, 47, 452-455.	1.5	5
188	Pheochromocytoma: Gasping for Air. Hormones and Cancer, 2015, 6, 191-205.	4.9	26
189	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	3.9	25
190	Models of parent-of-origin tumorigenesis in hereditary paraganglioma. Seminars in Cell and Developmental Biology, 2015, 43, 117-124.	5.0	22
191	Candidate colorectal cancer predisposing gene variants in Chinese early-onset and familial cases. World Journal of Gastroenterology, 2015, 21, 4136.	3.3	10
192	Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 361-368.	0.5	24
193	Pheochromocytoma and Paraganglioma. Endocrine Practice, 2015, 21, 406-412.	2.1	54
194	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
195	Identification of novel hereditary cancer genes by whole exome sequencing. Cancer Letters, 2015, 369, 274-288.	7.2	31
196	15 YEARS OF PARAGANGLIOMA: Pheochromocytoma, paraganglioma and genetic syndromes: a historical perspective. Endocrine-Related Cancer, 2015, 22, T147-T159.	3.1	13

#	Article	IF	Citations
197	Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. Journal of Medical Genetics, 2015, 52, 647-656.	3.2	102
198	Adrenal Tumors in Adults. Surgical Pathology Clinics, 2015, 8, 725-749.	1.7	13
199	Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 484-500.	1.9	91
200	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nature Reviews Endocrinology, 2015, 11, 101-111.	9.6	396
201	Tumors of the Adrenal Gland. , 2015, , 321-357.		0
202	Myc and its interactors take shape. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 469-483.	1.9	102
203	Hereditary Syndromes Involving Pheochromocytoma and Paraganglioma. , 2016, , 221-234.		1
204	Endocrine Hypertension. , 2016, , 556-588.		8
205	Pheochromocytoma and paraganglioma. Current Opinion in Oncology, 2016, 28, 5-10.	2.4	40
206	Germline compound heterozygous poly-glutamine deletion inUSF3may be involved in predisposition to heritable and sporadic epithelial thyroid carcinoma. Human Molecular Genetics, 2016, 26, ddw382.	2.9	14
207	GEP- NETS UPDATE: Genetics of neuroendocrine tumors. European Journal of Endocrinology, 2016, 174, R275-R290.	3.7	55
208	Diagnosis and Management of Hereditary Phaeochromocytoma and Paraganglioma. Recent Results in Cancer Research, 2016, 205, 105-124.	1.8	6
209	Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome. Pathology and Oncology Research, 2016, 22, 673-679.	1.9	13
210	Recently characterized molecular events in uncommon gynaecological neoplasms and their clinical importance. Histopathology, 2016, 69, 903-913.	2.9	17
211	<scp>HRAS</scp> mutation prevalence and associated expression patterns in pheochromocytoma. Genes Chromosomes and Cancer, 2016, 55, 452-459.	2.8	28
212	Precision medicine in pheochromocytoma and paraganglioma: current and future concepts. Journal of Internal Medicine, 2016, 280, 559-573.	6.0	49
213	Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. , 2016, , .		6
214	Germline mutations and genotypeâ€“phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2016, 175, 311-323.	3.7	27

#	Article	IF	Citations
215	Missing heritability of complex diseases: Enlightenment by genetic variants from intermediate phenotypes. BioEssays, 2016, 38, 664-673.	2.5	52
216	Phaeochromocytoma and Paraganglioma. Advances in Experimental Medicine and Biology, 2016, 956, 239-259.	1.6	49
217	Tracking Cancer Genetic Evolution using OncoTrack. Scientific Reports, 2016, 6, 29647.	3.3	5
218	Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nature Communications, 2016, 7, 11263.	12.8	73
219	The future of clinical cancer genomics. Seminars in Oncology, 2016, 43, 615-622.	2.2	23
220	Head and Neck Paragangliomas. , 2016, , 693-709.		0
221	Social stress in adolescents induces depression and brain-region-specific modulation of the transcription factor MAX. Translational Psychiatry, 2016, 6, e914-e914.	4.8	22
223	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Medicine, 2016, 8, 116.	8.2	15
224	Identification of eight novel SDHB, SDHC, SDHD germline variants in Danish pheochromocytoma/paraganglioma patients. Hereditary Cancer in Clinical Practice, 2016, 14, 13.	1.5	13
225	Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. Endocrine Practice, 2016, 22, 302-314.	2.1	110
226	The Rise and Rise of Exome Sequencing. Public Health Genomics, 2016, 19, 315-324.	1.0	15
227	The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cellular Oncology (Dordrecht), 2016, 39, 491-510.	4.4	34
228	Malignant pheochromocytomas/paragangliomas harbor mutations in transport and cell adhesion genes. International Journal of Cancer, 2016, 138, 2201-2211.	5.1	24
229	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene, 2016, 35, 1080-1089.	5.9	50
230	Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and Erythrocytosis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 453-460.	3.6	47
231	Bronchial Paraganglioma with SDHB Deficiency. Endocrine Pathology, 2016, 27, 332-337.	9.0	4
232	Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1034-1043.	3.6	29
233	Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Critical Reviews in Oncology/Hematology, 2016, 100, 190-208.	4.4	89

#	Article	IF	Citations
234	Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics, 2016, 48, 59-66.	21.4	253
235	Pheochromocytoma and Paraganglioma. Hematology/Oncology Clinics of North America, 2016, 30, 135-150.	2.2	127
237	Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. FASEB Journal, 2017, 31, 2226-2240.	0.5	12
238	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications, 2017, 8, 14674.	12.8	53
239	Childhood cancer predisposition syndromesâ€"A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
240	Next Generation Sequencing Based Clinical Molecular Diagnosis of Human Genetic Disorders. , 2017, , .		2
241	MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. Nucleic Acids Research, 2017, 45, 2396-2407.	14.5	69
242	Von Hippelâ€"Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clinical Cancer Research, 2017, 23, e68-e75.	7.0	205
243	Review of sequencing platforms and their applications in phaeochromocytoma and paragangliomas. Critical Reviews in Oncology/Hematology, 2017, 116, 58-67.	4.4	34
244	Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3296-3305.	3.6	220
245	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncology, 2017, 3, 1204.	7.1	149
246	Precision Medicine in Adrenal Disorders: the Next Generation. Endocrine Practice, 2017, 23, 672-679.	2.1	3
247	Precision Medicine: An Update on Genotype/Biochemical Phenotype Relationships in Pheochromocytoma/Paraganglioma Patients. Endocrine Practice, 2017, 23, 690-704.	2.1	58
248	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. Journal of Pathology, 2017, 242, 273-283.	4.5	9
249	Genetics of Pheochromocytomas and Paragangliomas. Endocrinology and Metabolism Clinics of North America, 2017, 46, 459-489.	3.2	9
250	The role of microRNAs in the pathophysiology of adrenal tumors. Molecular and Cellular Endocrinology, 2017, 456, 36-43.	3.2	20
251	Molecular Genetics of Pheochromocytoma and Paraganglioma. , 2017, , 15-45.		0
252	Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence. British Journal of Cancer, 2017, 117, 1689-1701.	6.4	58

#	Article	IF	Citations
253	Genetic mechanisms of human hypertension and their implications for blood pressure physiology. Physiological Genomics, 2017, 49, 630-652.	2.3	32
254	Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancerâ€"Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clinical Cancer Research, 2017, 23, 6315-6324.	7.0	73
255	Global DNA Methylation Analysis Identifies Two Discrete clusters of Pheochromocytoma with Distinct Genomic and Genetic Alterations. Scientific Reports, 2017, 7, 44943.	3.3	13
256	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocrine Reviews, 2017, 38, 489-515.	20.1	241
257	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
258	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. Endocrine Pathology, 2017, 28, 302-307.	9.0	25
259	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery, 2017, 161, 230-239.	1.9	60
260	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247.	9.6	198
261	Management of Adrenal Masses in Children and Adults. , 2017, , .		5
262	Management of Locally Advanced and Metastatic Pheochromocytoma and Paraganglioma. , 2017, , 277-300.		1
263	Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery, 2017, 161, 220-227.	1.9	47
264	Nonfunctioning Adrenal Pheochromocytoma Incidentally Discovered Associated with Renal Oncocytoma. Journal of Onco-Nephrology, 2017, 1, 62-65.	0.6	3
265	Application of Next-Generation Sequencing in the Era of Precision Medicine. , 0, , .		7
266	Mitochondrial Deficiencies in the Predisposition to Paraganglioma. Metabolites, 2017, 7, 17.	2.9	21
267	MYC Deregulation in Primary Human Cancers. Genes, 2017, 8, 151.	2.4	281
268	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. International Journal of Molecular Sciences, 2017, 18, 308.	4.1	353
269	Review of Pediatric Pheochromocytoma and Paraganglioma. Frontiers in Pediatrics, 2017, 5, 155.	1.9	90
270	The clinical genetics of phaeochromocytoma and paraganglioma. Archives of Endocrinology and Metabolism, 2017, 61, 490-500.	0.6	17

#	Article	IF	Citations
271	Synchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report. Surgical Case Reports, 2017, 3, 131.	0.6	11
272	Normalization of Hypercalcemia Following Successful Treatment of Bilateral Pheochromocytomas Due to A MAX Gene Mutation. AACE Clinical Case Reports, 2017, 3, 367-369.	1.1	0
273	Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral Pheochromocytomas. Journal of the Endocrine Society, 2017, 1, 1401-1407.	0.2	49
274	Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs). Endocrine Regulations, 2018, 52, 41-54.	1.3	23
275	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1574-1582.	3.6	27
276	MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2018, 1861, 235-245.	1.9	7
277	Extent of surgery for phaeochromocytomas in the genomic era. British Journal of Surgery, 2018, 105, e84-e98.	0.3	31
278	The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Laboratory Investigation, 2018, 98, 414-426.	3.7	22
279	Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis. Cell and Tissue Research, 2018, 372, 379-392.	2.9	16
280	Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Annals of Surgical Oncology, 2018, 25, 1395-1402.	1.5	11
281	NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. American Journal of Surgical Pathology, 2018, 42, 636-645.	3.7	97
282	Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nature Communications, 2018, 9, 144.	12.8	197
283	MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. Journal of the National Cancer Institute, 2018, 110, 517-526.	6.3	9
284	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	6.2	284
286	Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocrine-Related Cancer, 2018, 25, L37-L42.	3.1	57
287	Routine genetic screening with a multi-gene panel in patients with pheochromocytomas. Endocrine, 2018, 59, 175-182.	2.3	29
288	Epigenetics of pheochromocytoma and paraganglioma. Molecular and Cellular Endocrinology, 2018, 469, 92-97.	3.2	12
289	Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management. Contemporary Endocrinology, 2018, , 261-310.	0.1	2

#	Article	IF	Citations
290	Pheochromocytomas and Paragangliomas: Genetics and Pathophysiology. Contemporary Endocrinology, 2018, , 173-196.	0.1	0
291	Clinical evaluation and treatment of phaeochromocytoma. Annals of Clinical Biochemistry, 2018, 55, 34-48.	1.6	32
292	Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms. Endocrine-Related Cancer, 2018, 25, T15-T28.	3.1	22
293	Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 46-55.	3.6	19
294	Succinate dehydrogenase (SDH)â€deficient neoplasia. Histopathology, 2018, 72, 106-116.	2.9	181
295	Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. European Journal of Endocrinology, 2018, 178, K1-K9.	3.7	19
296	Activating FGFR1 Mutations in Sporadic Pheochromocytomas. World Journal of Surgery, 2018, 42, 482-489.	1.6	13
297	Study of germline mutations in patients with pheochromocytoma and paraganglioma in a tertiary level university hospital: Which patients have been studied and what results have been found?. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2018, 65, 508-514.	0.2	0
298	An update on adrenal endocrinology: significant discoveries in the last 10Âyears and where the field is heading in the next decade. Hormones, 2018, 17, 479-490.	1.9	5
299	Calculating the statistical significance of rare variants causal for Mendelian and complex disorders. BMC Medical Genomics, 2018, 11, 53.	1.5	13
300	Estudio de mutaciones germinales en pacientes con feocromocitomas y paragangliomas atendidos en un hospital universitario de tercer nivel: Â¿quÃ© pacientes se estudian y quÃ© resultados se encuentran?. Endocrinologia, Diabetes Y NutriciÃ“n, 2018, 65, 508-514.	0.3	2
301	Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. Journal of Internal Medicine, 2019, 285, 187-204.	6.0	83
302	Characterization and metabolic synthetic lethal testing in a new model of SDH-loss familial pheochromocytoma and paraganglioma. Oncotarget, 2018, 9, 6109-6127.	1.8	13
303	Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma. International Journal of Genomics, 2018, 2018, 1-9.	1.6	4
304	Commentary: Postmicturition syndrome: a neglected syndrome dangerous for the bladder and the heart. Journal of the American Society of Hypertension, 2018, 12, 594-596.	2.3	0
305	Secondary Hypertension. , 2018, , 136-143.		1
306	Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors. Oncology Letters, 2018, 16, 3070-3082.	1.8	2
308	SDHD Gene Mutations: Looking Beyond Head and Neck Tumors. AACE Clinical Case Reports, 2018, 4, 186-190.	1.1	0

#	Article	IF	Citations
309	Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine. Journal of Clinical Medicine, 2018, 7, 242.	2.4	63
310	Cuando el cÃ¡ncer es una enfermedad rara. Arbor, 2018, 194, 464.	0.3	2
312	Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2018, 29, 169-175.	9.0	26
313	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer, 2018, 25, T201-T219.	3.1	52
314	The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis. Frontiers of Medicine, 2018, 12, 412-425.	3.4	187
315	Complex Landscape of Germline Variants in Brazilian Patients With Hereditary and Early Onset Breast Cancer. Frontiers in Genetics, 2018, 9, 161.	2.3	21
316	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
317	Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1779-1789.	3.6	5
318	Genetic Testing in Hereditary Colorectal Cancer. , 2018, , 209-232.		0
319	Functional interplay between câ€Myc and Max in B lymphocyte differentiation. EMBO Reports, 2018, 19, .	4.5	20
320	Pheochromocytoma: When to search a germline defect?. Presse Medicale, 2018, 47, e109-e118.	1.9	10
321	Case Report of Bilateral Pheochromocytomas due to a Novel Max Mutation in a Patient Known to have a Pituitary Prolactinoma. AACE Clinical Case Reports, 2018, 4, e453-e456.	1.1	13
322	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18.	6.2	46
323	Heritable and Syndromic Pheochromocytoma and Paraganglioma. Contemporary Endocrinology, 2018, , 63-87.	0.1	0
324	An Update on the Histology of Pheochromocytomas: How Does it Relate to Genetics?. Hormone and Metabolic Research, 2019, 51, 403-413.	1.5	6
325	Pheochromocytoma and Paraganglioma. New England Journal of Medicine, 2019, 381, 552-565.	27.0	437
326	Max deletion destabilizes MYC protein and abrogates EÂµ-Myc lymphomagenesis. Genes and Development, 2019, 33, 1252-1264.	5.9	41
327	Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?. Current Cardiology Reports, 2019, 21, 104.	2.9	16

#	Article	IF	Citations
328	A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas. Neoplasma, 2019, 66, 671-680.	1.6	21
329	Pheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance. Archives of Endocrinology and Metabolism, 2019, 63, 369-375.	0.6	8
330	Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin. Cancers, 2019, 11, 1070.	3.7	35
331	A nomogram for predicting the presence of germline mutations in pheochromocytomas and paragangliomas. Endocrine, 2019, 66, 666-672.	2.3	8
332	A novel individualized drug repositioning approach for predicting personalized candidate drugs for type 1 diabetes mellitus. Statistical Applications in Genetics and Molecular Biology, 2019, 18, .	0.6	1
333	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. Cancers, 2019, 11, 809.	3.7	23
334	Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations. BMC Cancer, 2019, 19, 619.	2.6	6
335	Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background. Cancers, 2019, 11, 743.	3.7	6
336	Contemporary pharmacogenetic assays in view of the PharmGKB database. Pharmacogenomics, 2019, 20, 261-272.	1.3	13
337	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. American Journal of Human Genetics, 2019, 104, 651-664.	6.2	51
338	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. Cancers, 2019, 11, 436.	3.7	33
339	Malignant Pheochromocytoma. , 2019, , 460-468.		0
341	New and Emerging Biomarkers in Endocrine Pathology. Advances in Anatomic Pathology, 2019, 26, 198-209.	4.3	11
342	Novel TMEM127 Variant Associated to Bilateral Phaeochromocytoma with an Uncommon Clinical Presentation. Case Reports in Endocrinology, 2019, 2019, 1-5.	0.4	3
343	The Identification of Differentially Expressed Genes Showing Aberrant Methylation Patterns in Pheochromocytoma by Integrated Bioinformatics Analysis. Frontiers in Genetics, 2019, 10, 1181.	2.3	4
344	Pheochromocytoma/Paraganglioma: Management, Genetics, and Follow-up. , 2019, , 469-477.		0
346	Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 117-128.	1.2	40
347	Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine. Human Molecular Genetics, 2020, 29, R128-R137.	2.9	21

#	Article	IF	Citations
348	Caveat for Vascular Surgeons: Lesson Learned from Acute Onset of a Rare Aortic Paraganglioma in a Young Boy. Annals of Vascular Surgery, 2020, 66, 667.e1-667.e7.	0.9	0
349	Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients. Frontiers in Endocrinology, 2020, 11, 587769.	3.5	15
350	Identification of Novel Mutations and Expressions of EPAS1 in Phaeochromocytomas and Paragangliomas. Genes, 2020, 11, 1254.	2.4	10
351	A Novel Phenotype of Germline Pathogenic Variants in MAX: Concurrence of Pheochromocytoma and Ganglioneuroma in a Chinese Family and Literature Review. Frontiers in Endocrinology, 2020, 11, 558.	3.5	4
353	A Novel MAX Gene Mutation Variant in a Patient With Multiple and â€œCompositeâ€• Neuroendocrineâ€“Neuroblastic Tumors. Frontiers in Endocrinology, 2020, 11, 234.	3.5	18
354	Bilateral pheochromocytoma: Clinical characteristics, treatment and longitudinal followâ€up. Clinical Endocrinology, 2020, 93, 288-295.	2.4	18
355	MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer. Cancer Cell, 2020, 38, 97-114.e7.	16.8	46
356	A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1519-1534.	2.5	10
357	Pheochromocytomas and paragangliomas in children: Data from the Italian Cooperative Study (TREP). Pediatric Blood and Cancer, 2020, 67, e28332.	1.5	12
358	MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression. PLoS Genetics, 2020, 16, e1008803.	3.5	14
359	An overview of 20Âyears of genetic studies in pheochromocytoma and paraganglioma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101416.	4.7	106
360	Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion. Hormone and Metabolic Research, 2020, 52, 784-787.	1.5	9
361	Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1051-1063.	2.5	30
362	Pheochromocytomas in Complex Genetic Disorders. Endocrinology, 2021, , 325-344.	0.1	0
363	Pheochromocytoma/Paraganglioma, Medullary Thyroid Carcinoma, and Hereditary Endocrine Neoplasia Syndromes. , 2021, , 491-527.		1
364	Pheochromocytoma and Paraganglioma. , 2021, , 101-137.		0
365	What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. Endocrine Pathology, 2021, 32, 134-153.	9.0	22
367	Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry. Endocrine Pathology, 2021, 32, 228-244.	9.0	29

#	Article	IF	Citations
368	Genetics of Acromegaly and Gigantism. Journal of Clinical Medicine, 2021, 10, 1377.	2.4	21
369	Genetics of pheochromocytoma and paraganglioma. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 283-290.	2.3	22
370	Pseudohypoxic pheochromocytomas and paragangliomas dominate in children. Pediatric Blood and Cancer, 2021, 68, e28981.	1.5	14
371	Case Report: Pheochromocytoma and Synchronous Neuroblastoma in a Family With Hereditary Pheochromocytoma Associated With a MAX Deleterious Variant. Frontiers in Endocrinology, 2021, 12, 609263.	3.5	4
372	Clinical description & molecular modeling of novel MAX pathogenic variant causing pheochromocytoma in family, supports paternal parent-of-origin effect. Cancer Genetics, 2021, 252-253, 107-110.	0.4	2
373	Mutation Profile of Aggressive Pheochromocytoma and Paraganglioma with Comparison of TCGA Data. Cancers, 2021, 13, 2389.	3.7	7
374	Familial Acromegaly and Bilateral Asynchronous Pheochromocytomas in a Female Patient With a MAX Mutation: A Case Report. Frontiers in Endocrinology, 2021, 12, 683492.	3.5	6
375	GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma. Cell Death and Disease, 2021, 12, 444.	6.3	8
376	Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clinical and Translational Oncology, 2021, 23, 1995-2019.	2.4	69
377	A Novel, Likely Pathogenic MAX Germline Variant in a Patient With Unilateral Pheochromocytoma. Journal of the Endocrine Society, 2021, 5, bvab085.	0.2	1
378	Pheochromocytoma. American Journal of Surgical Pathology, 2021, 45, 1155-1165.	3.7	10
379	Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma. Cancers, 2021, 13, 4219.	3.7	3
380	The Multiple Faces of MNT and Its Role as a MYC Modulator. Cancers, 2021, 13, 4682.	3.7	6
381	MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2024824118.	7.1	9
382	Genetics of Pituitary Tumours. Experientia Supplementum (2012), 2019, 111, 171-211.	0.9	6
383	Inherited Neuroendocrine Neoplasms. , 2021, , 409-459.		7
384	Genetics of Pheochromocytoma and Paraganglioma. , 2017, , 85-103.		1
385	Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1163-e1182.	3.6	43

#	Article	IF	Citations
386	Evaluation of Head and Neck Paragangliomas by Computed Tomography in Patients with Pheochromocytoma-Paraganglioma Syndromes. Polski Przeglad Radiologii I Medycyny Nuklearnej, 2016, 81, 510-518.	1.0	6
387	Progenitor Cell Line (hPheo1) Derived from a Human Pheochromocytoma Tumor. PLoS ONE, 2013, 8, e65624.	2.5	41
388	Reverse Engineering the Neuroblastoma Regulatory Network Uncovers MAX as One of the Master Regulators of Tumor Progression. PLoS ONE, 2013, 8, e82457.	2.5	13
389	Molecular and Cellular Features of Murine Craniofacial and Trunk Neural Crest Cells as Stem Cell-Like Cells. PLoS ONE, 2014, 9, e84072.	2.5	15
390	Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomasâ€“Effect of Different Statins on Mouse Pheochromocytoma Cells. PLoS ONE, 2014, 9, e97712.	2.5	24
391	XomAnnotate: Analysis of Heterogeneous and Complex Exome- A Step towards Translational Medicine. PLoS ONE, 2015, 10, e0123569.	2.5	5
392	Biophysical characterization of the b-HLH-LZ of Î”Max, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers. PLoS ONE, 2017, 12, e0174413.	2.5	11
393	Personalized diagnostics of chromaffin tumors (pheochromocytoma, paraganglioma) in oncoendocrinology. Endocrine Surgery, 2018, 12, 19-39.	0.2	4
394	Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects. Journal of Endocrinology, 2019, 240, R21-R45.	2.6	55
395	Genetics of Pheochromocytoma and Paraganglioma. , 0, , 1-22.		5
396	Molecular markers of paragangliomas/pheochromocytomas. Oncotarget, 2017, 8, 25756-25782.	1.8	36
397	ARHI is a novel epigenetic silenced tumor suppressor in sporadic pheochromocytoma. Oncotarget, 2017, 8, 86325-86338.	1.8	3
398	Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma. Oncotarget, 2019, 10, 5919-5931.	1.8	17
399	Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methylation of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic. Oncotarget, 2015, 6, 21493-21506.	1.8	26
400	Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review. Iranian Journal of Pathology, 2017, 12, 313-322.	0.5	8
401	HIF Signaling Pathway in Pheochromocytoma and Other Neuroendocrine Tumors. Physiological Research, 2014, 63, S251-S262.	0.9	42
402	Pheochromocytoma and paraganglioma syndromes: genetics and management update. Current Oncology, 2014, 21, 8.	2.2	102
403	Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma. Mathematical Biosciences and Engineering, 2019, 16, 7217-7229.	1.9	5

#	Article	IF	Citations
404	A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2Î± as the major player in its pathogenesis and future therapeutic options. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2014, 158, 175-180.	0.6	10
405	Cancer of the Adrenal Gland. UNIPA Springer Series, 2021, , 933-955.	0.1	0
406	Metastatic cluster 2-related pheochromocytoma/paraganglioma: a single-center experience and systematic review. Endocrine Connections, 2021, 10, 1463-1476.	1.9	3
407	MYCN and MAX alterations in Wilms tumor and identification of novel N-MYC interaction partners as biomarker candidates. Cancer Cell International, 2021, 21, 555.	4.1	10
408	Pheochromocytoma and NF1. , 2012, , 381-392.		0
409	Maternal Tumours Associated with and Influenced by Pregnancy. , 2012, , 389-441.		0
411	Skull Base Tumors: Viewpointâ€"Fractionated Radiotherapy or Stereotactic Radiotherapy. , 2015, , 517-527.		0
413	Pathophysiology of Pediatric Hypertension. , 2016, , 1951-1995.		0
414	Adrenal Neuroendocrine Tumors: Pheochromocytoma and Neuroblastic Tumors. , 2016, , 323-357.		0
415	Adrenal Tumors, Molecular Pathogenesisâ˜†. , 2016, , .		0
416	Inherited Breast Cancer. , 2016, , 315-327.		0
418	Diagnosing Hereditary Cancer Susceptibility Through Multigene Panel Testing. , 2017, , 123-153.		0
419	Paroxysmal Hypertension: Pheochromocytoma. Updates in Hypertension and Cardiovascular Protection, 2018, , 541-560.	0.1	0
420	Genomic Applications and Insights in Unravelling Cancer Signalling Pathways. , 2019, , 471-511.		0
421	Pheochromocytomas in Complex Genetic Disorders. Endocrinology, 2019, , 1-20.	0.1	0
422	Clinical Challenges in Nonfunctional Pheochromocytomas. World Journal of Endocrine Surgery, 2019, 11, 86-90.	0.0	2
424	Progress in the diagnosis and treatment of paraganglioma. Translational Cancer Research, 2019, 8, 2624-2635.	1.0	3
425	Monogenic Hypertension. , 2020, , 639-681.		0

#	Article	IF	Citations
426	Metabolism and secretion mechanism of catecholamine syndrome and related treatment strategies. Journal of Xiangya Medicine, 0, 5, 39-39.	0.2	1
428	Next-generation sequencing for cancer diagnostics: a practical perspective. Clinical Biochemist Reviews, 2011, 32, 177-95.	3.3	271
429	Pheochromocytoma: implications in tumorigenesis and the actual management. Minerva Endocrinologica, 2012, 37, 141-56.	1.8	19
430	Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing. Iranian Journal of Public Health, 2015, 44, 1348-52.	0.5	3
431	Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. Clinical Biochemist Reviews, 2017, 38, 69-100.	3.3	46
432	Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review. Iranian Journal of Pathology, 2017, 12, 313-322.	0.5	5
433	The systems of metastatic potential prediction in pheochromocytoma and paraganglioma. American Journal of Cancer Research, 2020, 10, 769-780.	1.4	10
434	Familial Syndromes and Genetic Causes of Paraganglioma and Phaeochromocytoma. , 2022, , 1061-1068.		0
436	<scp>CIBERER</scp>: Spanish national network for research on rare diseases: A highly productive collaborative initiative. Clinical Genetics, 2022, 101, 481-493.	2.0	9
437	Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach. International Journal of Molecular Sciences, 2022, 23, 1450.	4.1	9
438	SDHB and SDHD silenced pheochromocytoma spheroids respond differently to tumour microenvironment and their aggressiveness is inhibited by impairing stroma metabolism. Molecular and Cellular Endocrinology, 2022, 547, 111594.	3.2	5
439	Normal and Neoplastic Growth Suppression by the Extended Myc Network. Cells, 2022, 11, 747.	4.1	11
440	Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Endocrine Pathology, 2022, 33, 197-227.	9.0	24
442	A case of malignant pheochromocytoma of the adrenal gland in a young female. Annals of Urologic Oncology, 2021, , 48-55.	0.1	0
444	Polycomb group ring finger protein 6 suppresses Myc-induced lymphomagenesis. Life Science Alliance, 2022, 5, e202101344.	2.8	4
449	Identification of three new variants of SDHx genes in a cohort of Portuguese patients with extra-adrenal paragangliomas. Journal of Endocrinological Investigation, 2012, 35, 975-80.	3.3	4
450	Bilateral Pheochromocytoma with Germline MAX Variant without Family History. Clinics and Practice, 2022, 12, 299-305.	1.4	0
451	Metastatic pheochromocytomas and paragangliomas: where are we?. Tumori, 2022, 108, 526-540.	1.1	4

#	Article	IF	Citations
452	Bilateral Pheochromocytoma in a Patient With MYC-Associated Protein X (MAX) Genetic Predisposition. , 2023, , 153-155.		0
453	Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours. Endocrine-Related Cancer, 2022, 29, R157-R172.	3.1	4
454	The Classic, the Trendy, and the Refashioned: A Primer for Pathologists on What Is New in Familial Endocrine Tumor Syndromes. Advances in Anatomic Pathology, 2023, 30, 69-78.	4.3	3
455	Advances in Adrenal and Extra-adrenal Paraganglioma: Practical Synopsis for Pathologists. Advances in Anatomic Pathology, 0, Publish Ahead of Print, .	4.3	4
456	Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment. Nature Communications, 2022, 13, .	12.8	16
458	Hereditary Cancer and Cancer Predisposition Syndromes. Advances in Molecular Pathology, 2022, 5, 9-27.	0.4	0
459	Hereditary Endocrine Tumour Registries. Journal of the Endocrine Society, 0, , .	0.2	0
460	Primary Hyperparathyroidism in a Patient With Bilateral Pheochromocytoma and a Mutation in the Tumor Suppressor MAX. , 2022, 1, .		1
461	The â€œextreme phenotype approachâ€•applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles. Oncotarget, 2023, 14, 111-125.	1.8	0
462	Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning. Molecular Medicine, 2023, 29, .	4.4	6
463	Succinate Dehydrogenase Mutations as Familial Pheochromocytoma Syndromes. Surgical Oncology Clinics of North America, 2023, 32, 289-301.	1.5	0
464	Tumour microenvironment in pheochromocytoma and paraganglioma. Frontiers in Endocrinology, 0, 14, .	3.5	5
465	Molecular Diagnosis of Genetic Diseases of the Kidney: Primer for Pediatric Nephrologists. , 2023, , 119-169.		0
466	Pituitary Tumorigenesisâ€”Implications for Management. Medicina (Lithuania), 2023, 59, 812.	2.0	0
467	Solid Swellings of the Anterior Triangle: Carotid Body Tumors. , 2023, , 249-265.		0
468	CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression. Hepatology Communications, 2023, 7, .	4.3	1
469	Rare forms of hereditary endocrine neoplasia: co-existence of pituitary adenoma and pheochromocytoma/paraganglioma. Problemy Endokrinologii, 2023, 69, 24-30.	0.8	0
470	Chromosome 14. , 2023, , 19-61.		0

#	Article	IF	Citations
471	Paragangliomas. , 2016, , 723-743.		0
472	Secondary Hypertension: Pheochromocytoma and Paraganglioma. , 2024, , 187-197.		0
474	Genetics of hereditary forms of primary hyperparathyroidism. Hormones, 2024, 23, 3-14.	1.9	3
475	A recurrent de novo MAX p.Arg60Gln variant causes a syndromic overgrowth disorder through differential expression of c-Myc target genes. American Journal of Human Genetics, 2023, , .	6.2	0
476	Wilms tumour resulting from paternal transmission of a TRIM28 pathogenic variantâ€"A first report. European Journal of Human Genetics, 0, , .	2.8	1
477	Updates on the genetics of multiple endocrine neoplasia. Annales D'Endocrinologie, 2024, 85, 127-135.	1.4	0
478	Genetic diagnosis in acromegaly and gigantism: From research to clinical practice. Best Practice and Research in Clinical Endocrinology and Metabolism, 2024, 38, 101892.	4.7	0